Tagraxofusp (SL-401)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Tagraxofusp (SL-401), covering 2025-01-06 to 2025-11-04. Get the full timeline:
Most recent: Clinical Trial Update: SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [Phase 1]